In mid-January 2022, the members of the executive committee of Pfizer Inc. (Pfizer), a global pharmaceutical enterprise headquartered in New York, were facing a strategic dilemma. Having just received the company’s full financial results for the year ending December 2021, they were preparing for an upcoming conference call with analysts where, in addition to making these results public, they had to also provide revenue guidance for the year ending .....more